Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1996-08-12
1997-09-16
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514617, A61K 3119, A61K 31165
Patent
active
056681755
ABSTRACT:
In accordance with the present invention, there is provided a method for the treatment of subjects afflicted with steroid or steroid-like hormone-responsive disease states. The invention method comprises administering to the subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with the steroid or steroid-like hormone-responsive disease state, wherein said ligand interacts with said receptor subtype to a significantly greater extent than with other subtypes of the same receptor class.
REFERENCES:
Astrom et al., "Retinoic Acid And Synthetic Analogs Differentially Activate Retinoic Acid Receptor Dependent Transcription", Biochemical and Biophysical Research Communications 173(1): 339-345 (1990).
Crettaz et al., "Liquid specificities of recombinant retinoic acid receptors RAR.alpha. and RAR.beta.", The Biochemical Journal 272(2):391-397 (1990).
Delescluse et al., "Selective High Affinity Retinoic Acid Receptor .alpha. or .beta.-.gamma. Ligands", Molecular Pharmacology 40(4):556-562 (1991).
Frey et al., "Antiproliferative activity of retinoids, interferon .alpha. and their combination in five human transformed cell lines", Cancer Letters 57:223-227 (1991).
Graupner et al., "6'-Substituted Naphthalene-2-Carboxylic Acid Analogs, A New Class Of Retinoic Acid Receptor Subtype-Specific Ligands" Biochemical and Biophysical Research Communications 179(3):1554-1561 (1991).
Kagechka et al., "Differentiation Inducers of Human Promyelocytic Leukemia Cells HL-60'" Chem. Pharm. Bull. 34(5):2275-2278 (1986).
Kakizuka et al., "Molecular Cloning and Characterization of Aberrant Retinoic Acid Receptors From A t(15;17) Positive Acute Promyelocytic Leukemia Patient", Journal of Cellular Biochemistry vol. Supplement No. 15G, p. 31 (Apr. 1991).
Lehmann et al., "Identification of Retinoids with Nuclear Receptor Subtype-selective Activities", Cancer Research 51:4804-4809 (1991).
Reynolds, J.E.F., "Martindale The Extra Pharmacopoeia" The Pharmaceutical Press, London, Acitretin, p. 916 (1989).
Berger Christina S.
Evans Ronald M.
Heyman Richard A.
Stein Robert B.
Jordan Kimberly
Reiter Stephen E.
The Salk Institute for Biological Studies
LandOfFree
Use of selective ligands for treatment of disease states respons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of selective ligands for treatment of disease states respons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of selective ligands for treatment of disease states respons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218793